Products / Services

At present, the company has established extensive, in-depth and long-term cooperative relationships with many hospitals, and researches on multiple cancers such as lung cancer, colorectal cancer and gynecological tumors. The research direction covers the screening of early tumor markers and the prognosis. evaluation, tumor heterogeneity molecular classification and other fields, and

achieved fruitful results.

Genecast MRD-CRC

Genecast MRD – CRC is our NGS-based large panel MRD test, which detects MRD using our MinerVa platform and provides postoperative monitoring, recurrence risk assessment for early-stage colorectal cancer patients, as well as an adjuvant chemotherapy targeted therapy recommendation for stage III colorectal cancer patients. 


Genecast MRD – CRC Assay uses a fixed panel of 769 genes to detect personalized tumor gene mutations in DNA extracted from FFPE tissue samples and ctDNA extracted from liquid biopsy samples of the patient and provides postoperative monitoring of the patient’s MRD status to measure the dynamic changes in the tumor load. 


In addition, Genecast MRD – CRC provides adjuvant chemotherapy targeted therapy recommendation for stage III colorectal cancer patients.